A treatment for polycystic kidney disease (PKD), a leading cause of fatal kidney failure worldwide, has been identified by a research team led by Yale biochemist Craig Crews, according to a report in the Proceedings of the National Academy of Sciences.
The largest study ever conducted on acne and stress reveals that teenagers who were under high levels of stress were 23 percent more likely to have increased acne severity, according to researchers from Wake Forest University School of Medicine and colleagues.
Scientists at University College London (UCL) have conducted the first clinical trial to demonstrate that an intensive treatment for periodontitis (gum disease) directly improves the health of blood vessels.
In the largest study of its kind, surgeons at Hospital for Special Surgery have determined that by modifying a classic ligament surgery, they can return more athletes, such as baseball players, to their prior level of competition.
In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90 percent of cases refractory to standard therapies.
Scientists and public health officials, wary that the H5N1 avian influenza virus could trigger an influenza pandemic, have looked to past pandemics, including the 1918 “Spanish Flu,” for insight into pandemic planning.
The Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn’s disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.
An estimated 10 million Americans have osteoporosis, and an additional 34 million are estimated to have low bone mass, placing them at increased risk for developing this condition.
The McGovern Institute for Brain Research at MIT announced today that David Julius, a physiologist at the University of California at San Francisco (UCSF), will be the 2007 recipient of the Edward M. Scolnick Prize in Neuroscience.
Research conducted at the Methodist DeBakey Heart Center in Houston shows that a combination statin therapy lowers bad cholesterol by an unprecedented 70 percent, and has the added benefit of reducing life-threatening inflammation that can lead to heart disease and stroke.